|By Marketwired .||
|July 10, 2014 03:00 PM EDT||
CAMBRIDGE, MA -- (Marketwired) -- 07/10/14 -- A new clinical study published in today's issue of JAMA Ophthalmology has identified REBIScan's Pediatric Vision Scanner (PVS) as the superior approach to testing preschool children for eye problems. The study tested for amblyopia, also known as "lazy eye," and strabismus (misaligned eyes), which, combined, are the leading causes of preventable vision loss in the United States and globally.
Study author Reed Jost, senior author Dr. Eileen Birch, and their colleagues from the Retina Foundation of the Southwest tested 300 children using the PVS (and also using Welch Allyn's SureSight Autorefractor), then conducted eye examinations in all children. In an independent study supported by the Thrasher Research Fund, they found that the PVS significantly outperformed the SureSight in sensitivity, identifying 97% of children affected by the targeted conditions, and made significantly fewer unnecessary referrals of healthy children (better specificity). The authors noted that "The failure to detect amblyopia during early childhood... is a serious health problem" and that "The PVS (which assesses alignment of the two eyes) is quick and simple to use... and is more accurate than risk factor assessment."
In an accompanying editorial, Dr. Jonathan Holmes, Professor of Ophthalmology at the Mayo Clinic, stated, "Perhaps the PVS should be used as more than a screener... and should be incorporated into routine clinical assessment by eye care providers..."
The PVS was co-developed by REBIScan co-founder Dr. David Hunter, Ophthalmologist-in-Chief at Boston Children's Hospital. REBIScan CEO Justin Shaka stated, "The PVS is an enormous innovation in how vision screening will be performed in the future. As Dr. Holmes noted, these studies are redefining amblyopia and its treatment, and this is resonating with providers across the globe."
Each year, hundreds of thousands of children permanently lose sight due to lack of detection, yet with early detection the condition can be treated with glasses or an eye patch. REBIScan, Inc. is a medical device and data analytics firm based in Cambridge, Massachusetts, working to achieve FDA clearance for the device; Shaka anticipates that following regulatory approval commercial sales of the device will begin in 2015.
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
Jul. 25, 2016 02:00 PM EDT Reads: 934
Jul. 25, 2016 01:15 PM EDT Reads: 1,895
Jul. 25, 2016 01:00 PM EDT Reads: 1,924
Jul. 25, 2016 12:15 PM EDT Reads: 411
Jul. 25, 2016 12:00 PM EDT Reads: 1,813
Jul. 25, 2016 12:00 PM EDT Reads: 1,663
Jul. 25, 2016 11:45 AM EDT Reads: 864
Jul. 25, 2016 11:00 AM EDT Reads: 1,574
Jul. 25, 2016 11:00 AM EDT Reads: 898
Jul. 25, 2016 10:53 AM EDT Reads: 327
Jul. 25, 2016 10:30 AM EDT Reads: 1,938
Jul. 25, 2016 10:30 AM EDT Reads: 296
Jul. 25, 2016 10:15 AM EDT Reads: 1,865
Jul. 25, 2016 10:00 AM EDT Reads: 986
Cloud analytics is dramatically altering business intelligence. Some businesses will capitalize on these promising new technologies and gain key insights that’ll help them gain competitive advantage. And others won’t. Whether you’re a business leader, an IT manager, or an analyst, we want to help you and the people you need to influence with a free copy of “Cloud Analytics for Dummies,” the essential guide to this explosive new space for business intelligence.
Jul. 25, 2016 09:45 AM EDT Reads: 712